Enrollment Begins in Cytori Phase III/Pivotal ADRESU Urinary Incontinence Trial By: Benzinga via Benzinga September 03, 2015 at 07:04 AM EDT Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced that the first patient has been enrolled and treated in the ADRESU ... Read More >>